Key result
Rosuvastatin achieved higher LDL-C target attainment than atorvastatin, and the SLCO1B1 T/C genotype increased adverse effect risk vs T/T.
Why the study?
Does rosuvastatin compared to atorvastatin, and SLCO1B1 genotype, affect lipid-lowering response and adverse events in postmenopausal women?
Cohort (n=145)
Does rosuvastatin compared to atorvastatin, and SLCO1B1 genotype, affect lipid-lowering response and adverse events in postmenopausal women?
Answers are grounded in this paper and cite their sources.
In postmenopausal women, rosuvastatin demonstrated superior LDL-C lowering efficacy compared to atorvastatin, while the SLCO1B1 c.521T>C variant was a strong predictor of statin-related adverse effects.
Background: Interindividual differences in statin efficacy and tolerability are partly determined by genetic and metabolic factors. The SLCO1B1 c.521T>C polymorphism affects hepatic statin transport, while vitamin D deficiency may influence lipid metabolism and muscular tolerance. This study aimed to assess the impact of SLCO1B1 genotype and vitamin D status on lipid-lowering response and adverse events in postmenopausal women treated with atorvastatin or rosuvastatin. Methods: A total of 145 Croatian postmenopausal women were prospectively followed for 16 weeks. Participants received atorvastatin or rosuvastatin with dose titration to achieve low-density lipoprotein cholesterol (LDL-C) targets. Serum lipids, liver enzymes, and creatine kinase were monitored monthly. Serum levels of 25-hydroxyvitamin D were quantified by LC–MS/MS, while SLCO1B1 c.521T>C genotyping was performed using real-time PCR. Results: Rosuvastatin achieved a higher LDL-C target attainment rate compared with atorvastatin (81.1% vs. 67.6%, p = 0.02). The SLCO1B1 genotype was not associated with lipid response but was significantly associated with adverse effects. In multivariable regression analysis, patients with the T/C genotype had a significantly higher risk of developing adverse effects compared with those with the T/T genotype (OR 7.4, 95% Cl 2.1–26.7, p = 0.002). Vitamin D status showed no significant association with lipid outcomes or adverse events, although participants with severe deficiency exhibited a weaker LDL-C response. Conclusions: Rosuvastatin demonstrated superior lipid-lowering efficacy and tolerability compared with atorvastatin in postmenopausal women. The SLCO1B1 c.521T>C variant primarily affected safety rather than efficacy, while severe vitamin D deficiency might contribute to diminished statin response. Integrating pharmacogenetic and endocrine profiling could enhance individualized statin therapy and cardiovascular prevention in women.
No takes yet. Share an insight, caveat, or question.
Marušić et al. (2026) conducted a cohort in Hyperlipidemia (n=145). SLCO1B1 c.521T>C polymorphism (T/C genotype) vs. T/T genotype was evaluated on Adverse effects (OR 7.4, 95% CI 2.1-26.7, p=0.002). Rosuvastatin achieved higher LDL-C target attainment than atorvastatin, and the SLCO1B1 T/C genotype increased adverse effect risk vs T/T.
Synapse has enriched 10 related papers. Consider them for comparative context: